Aim
A European biotech company developing natural colorants wanted to ensure their production fungus was not only safe but genetically reliable. Their goal was to validate the strain’s identity, stability, and biosynthetic potential, thereby supporting regulatory submissions, partnerships, and long-term innovation.
Challenge
In today’s regulatory and industrial landscape, success depends not only on performance but on proof. Regulatory frameworks demand robust evidence that production strains are genetically stable, safe, and traceable over time. Although the company had generated extensive sequencing data, the challenge lay in transforming that raw information into a coherent, validated narrative — one that all stakeholders could trust. The data needed to go beyond sequence quality and demonstrate biosynthetic potential, genomic integrity, and reproducibility; until this was achieved, the strain’s full industrial potential remained untapped.
Solution
Sequentia Biotech designed a comprehensive genomic characterization workflow that focused on biological meaning rather than raw sequencing output. The pipeline included genome reconstruction, assembly validation, gene annotation, and functional pathway interpretation — all anchored in reproducible bioinformatics best practices.
Particular attention was given to the genes involved in pigment biosynthesis pathways, as well as genomic features related to safety and stability. The result was a detailed, multilayered understanding of the strain’s genetic architecture and functional landscape.
To ensure accessibility, our team delivered a visually clear, scientifically rigorous report designed for multidisciplinary audiences. Whether for R&D specialists, regulatory officers, or investors, the findings could be easily interpreted, communicated, and applied to strategic decision-making.
Impact
The validation pipeline confirmed that the fungus is genetically stable, biosafe, and ready for industrial deployment — a key milestone in the company’s path toward commercialization.
Beyond a single report, this collaboration established a bridge between science and strategy, connecting sequencing data with regulatory validation and research discovery with business opportunities. Multiple departments now rely on the analysis to guide R&D initiatives, support product registration, and communicate scientific credibility to partners and investors.
By transforming complexity into clarity, Sequentia Biotech provided the company with a durable, scalable foundation for growth, one that not only strengthens compliance and investor confidence but also opens new avenues for sustainable pigment innovation and next-generation biomanufacturing.
